Protective effects of DHEA and AED against viral, bacterial and parasitic infections

Israel Journal of Veterinary Medicine

Volumn 66, Issue 4, 2011, Pages 119-129

  Loria, R M ^a   Ben Nathan, D ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b KIMRON VETERINARY INSTITUTE   (Israel)

Author keywords

Androstenediol (AED); Bacterial; Dehydroepiandrosterone (DHEA); Infections; Parasitic; Viral

Indexed keywords

EID: 83655192430     PISSN: 03349152     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Seimenis, A.: Capacity building for zoonotic and foodborne diseases in the Mediterranean and Middle East regions (an in-tersectoral WHO/MZCP proposed strategy). Int. J. Antimi-crob. Agents 36S: S75-S79, 2010.
2. Böhm, M. White, P.C. Chambers, J. Smith, L. and Hutchings, M.R.: Wild deer as a source of infection for livestock and humans in the UK. Vet. J. 174:260-276. 2007.
3. Graham, J.P., Leibler, J.H., Price, L.B., Otte, J.M., Pfeifer, D.U., Tiensin, T., and Silbergeld A.K.: Te Animal-Human Interface and Infectious Disease in Industrial Food Animal Production: Rethinking Biosecurity and Biocontainment. Public Health Reports 123: 282-299, 2008.
4. Loria, R.M., Inge, T.H., Cook, S., Szakal, A., and Regelson, W.: Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J. Med. Virol. 26:301- 314, 1988.
5. Loria, R.M. and Padgett, D.A.: Androstenediol regulates systemic resistance against lethal infections in mice. Arch. Virol. 127:103-115, 1991.
6. Padgett, D.A., Loria, R.M., and Sheridan, J.F.: Endocrine regulation of the immune response to infuenza virus infection with a metabolite of DHEA-androstenediol. J Neuroimmunol. 78:203-211.1997.
7. Padgett, D.A. and Loria, R.M.: Endocrine regulation of murine macrophage function: efects of dehydroepiandrosterone, andros-tenediol, and androstenetriol. J. Neuroimmunol. 84:61-68, 1998.
8. Ben-Nathan, D., Padgett, D.A., and Loria, R.M.: Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and LPS toxicity. J. Med. Microbiol. 48:425-431, 1999.
9. Padgett, D.A. and Loria, R.M.: In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstenetriol. J. Immunol. 153:1544-1552, 1994.
10. Loria, R.M. and Padgett, D.A.: Androstenediol regulate systemic resistance against lethal infections in mice. NY Acad. Sci. 685:293-296.1993.
11. Loria, R.M., Conrad, D.H., Huf, H., and Ben-Nathan D.: An-drostenetriol and androstenediol protect against lethal radiation and restore radiation mediated immune injury. NY Acad. Sci. 917:860-868, 2000.
12. Marcu, A.C., Kielar, A.D., Paccionea, K.F., Barbee, W.R., Carter, H., Ivatury, R.R. ,Dielgelmann, R.F., Ward, K.R., and Loria, RM.: Androstenetriol Improves Survival in a Rodent Model of Traumatic Shock. Resuscitation 71:379-386, 2006.
13. Marcu, A.C., Paccionea, K.F., Barbee, W.R., Carter, H., Ivatury, R.R., Dielgelmann, R.F. Ward, K.R., and Loria, R.M.: Andros-tenetriol Immunomodulation Improves Survival Severe Trauma-Hemorrhage Shock Model. J.Trauma. 63: 662-699, 2007.
14. Loria, R.M., Padgett, D. A., and Phuong N. Huynh.: Regulation of the Immune Response by DHEA and its Metabolites. J. En-docrinol. 150:S209-S219,1996.
15. Morrison, D.C.: Bacterial endotoxins and pathogenesis. Rev. Infect. Dis. Suppl 4:S733-747. 1983.
16. Gadina, M., Bertini, R., Mengozzi, M., Zandalasini, M., Manto-vani, A., and Ghezzi, P.: Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensi-tive and glucocorticoid-resistant models of endotoxic shock. Exp. Med. 173:1305-1310, 1991.
17. Beutler, B. and Cerami. AC.: Te biology of cachectin/ TNF, a primary mediator of the host response. Annu. Rev. Immunol. 6:625-655, 1989.
18. Beutler, B.I.W. Milsark, and Cerama, A.C.: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229.869-871, 1985.
19. Vogel, S.N., Manthey, C.L., Perera, P.Y., Li, Z.Y., and Henricson, B.E.: Dissection of LPS-induced signaling pathways in murine macrophages using LPS analogs, LPS mimetics, and agents unrelated to LPS. Prog. Clin. Biol. Res. 392:421-431, 1995.
20. Valone, S.E., Rich, E.A, Wallis, R.S. and Ellner, J.J.: Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobac-terial antigens. Infect Immun. 56:3313-3315, 1988.
21. Jacobson, M.A., Fusaro, R.E., Galmarini, M., and Lang, W.: Decreased serum Dehydroepiandrosterone is associated with increased progression of human immunodefciency virus infection in men with CD4 cell counts of 200-499. J. Infect. Dis. 164:864-868, 1991.
22. Beutler, B.N. Krochin, I.W. Milsark, Luedke, C. and Cerami A.: Control of cachectin (tumor necrosis factor) synthesis: mechanism of endotoxin resistance. Science 232:977-980, 1986.
23. Waage, A. and Espevik, T.: Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J. Exp. Med. 167:1987-1992, 1988.
24. Lustig, S., Danenberg, H.D., Kafri, Y., Kobiler, D. and Ben-Nathan, D: Viral neuroinvasion and encephalitis induced by lipopol-ysaccharide and its mediators. J. Exp. Med. 176:707-712, 1992.
25. Danenberg, H.D., Alpert, G., Lustig, S., and Ben-Nathan, D.: De-hydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob. Agents Chemother. 36:2275-2279, 1992.
26. Waage, A. and Espevik, T.: Interleukin 1 potentiates the lethal effect of tumor necrosis factor a/cachectin in mice. J. Exp. Med. 167:1987-1992, 1988.
27. Zuckerman, S.H. and Evans, G.F.: Endotoxin tolerance: in vivo regulation of tumor necrosis factor and interleukin-1 synthesis is at the transcriptional level. Cell Immunol. 140:513-519, 1992.
28. Lehmann, V., Freudenberg, M.A., and Galanos, C.: Lethal tox-icity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J. Exp. Med.165:657-663, 1987.
29. Ben-Nathan, D. B., Lachmi, B., Lustig, S. and Feuerstein, G.: Protection by dehydroepiandrosterone in mice infected with viral encephalitis. Arch. Virol. 120:263-271, 1991.
30. Chang, C. C., Ou, Y.C., Raung, S.L and Chen C. J.: Antiviral effect of dehydroepiandrosterone on Japanese encephalitis virus infection. J. Gen. Virol. 86:2513-2523, 2005.
31. Negrette, B., Bonilla, E., Valero, N., Giraldoth, D., Medina-Leendertz, S., and Anez, F.: In mice the efciency of immunization with Venezuelan Equine Encephalomyelitis virus TC-83 is transiently increased by dehydroepiandrosterone. Invest. Clin. 42:235-240, 2001.
32. Schwartz, A.G.: Inhibition of spontaneous breast cancer formation in female C3H Avy/a by long treatment with dehydroepian-drosterone. Cancer Res. 39:1129-1132, 1979.
33. Araghi-Niknam, M., Zhang, Z., Jiang, S., Call, O., Eskelson, C.D., Watson, R.R.: Cytokine dysregulation and increased oxidation is prevented by dehydroepiandrosterone in mice infected with murine leukemia retrovirus. Proc. Soc. Exp. Biol. Med. 216:386-391, 1997.
34. Daigle, J., and D. J. Carr.: Androstenediol antagonizes herpes simplex virus type 1-induced encephalitis through the augmentation of type I IFN production. J. Immunol. 160:3060-3066, 1988.
35. Whitnall, M.H., Elliott, T.B., Harding R.A., Inal, C.E., Landau-er, M.R., Wilhelmsen, C.L., McKinney, L., Miner, V.L., Jackson, W.E., Loria, R.M., Ledney, G.D. and Seed, T.M. An-drostenediol stimulates myelopoiesis and enhances resistance to infection in gamma_irradiated mice Int. J. Immunopharmacol. 22:1-4, 2000.
36. Dos Santos, C. D., Toldo, M. P., and Do Prado, J.C.: Tryp-anosoma cruzi: the effects of dehydroepiandrosterone (DHEA) treatment during experimental infection. Acta Trop, 95: 109-115, 2005.
37. Leenstra, T., ter Kuile, F.O, Kariuki, S.K., Nixon, C.P., Oloo, A.J., Kager, P.A., and Kurtis, J.D.: Dehydroepiandrosterone sulfate levels associated with decreased malaria parasite density and increased hemoglobin concentration in pubertal girls from western Kenya. J. Infect. Dis. 188:297-304, 2003.
38. Rasmussen, K. R. and Healey, M.C.: Dehydroepiandrosterone-induced reduction of Cryptosporidium parvum infections in aged Syrian golden hamsters. J. Parasitol, 78: 554-557, 1992.
39. Schwartz, A.G. and Tannen, R.A.: Inhibition of 7,12-dimethyl benz(a)- anthracene and urethane-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandroster-one. Carcinogenesis 2:1335, 1981.
40. Li, S., Yan, X., Bélanger, A. and Labrie F.: Prevention by dehydroe-piandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res. Treat. 29:203-217, 1994.
41. Brazao, V., Santello, F. H., Caetano, L. C., Del Vecchio Filipin, M., Paula Alonso Toldo, M. and Do Prado, J. C.,: Immunomodula-tory efects of zinc and DHEA on the T-1 immune response in rats infected with Trypanosoma cruzi. Immunobiology, 215:427-434, 2010.
42. Santos, C.D., Loria, R.M., Oliveira, L.G., Kuehn, C.C., Tol-do, M.P., Albuquerque, S. and do Prado, J.C.: Efects of dehy-droepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two diferent Trypanosoma cruzi strains. Immunobiology. 215:980-986, 2010.
43. Vargas-villavicencio, J. A., Larralde, C. and Morales-Montor, J.: Treatment with dehydroepiandrosterone in vivo and in vitro inhibits reproduction, growth and viability of Taenia crassiceps metacestodes. Int. J. Parasitol, 38: 775-778, 2008.
44. Kuno, G. and Chang, GJ.: Biological Transmission of Arbovi-ruses: Reexamination of and New Insights into Components, Mechanisms, and Unique Traits as Well as Teir Evolutionary Trends. Clinical Microbiology Reviews, 18: 608-637, 2005.
45. Duane J. Gubler: Te Global Emergence/Resurgence of Arbovi-ral Diseases As Public Health Problems. Archives of Medical Research 33:330-342, 2002.
46. Weaver, S.C. and Reisen, W.K.: Present and Future Arboviral Treats. Antiviral Res. 85: 328, 2010.
47. Smithburn, K.C., Hughes, T.P., Burke, A.W. and Paul JH.: A neu-rotropic virus isolated from the blood of a native of Uganda. Am. J. Trop. Med. 30:471-492, 1940
48. Burke, S.D. and Monath, T.P: Flaviviruses. In Fields Virology Edited by: Field, B.N., Knipe, D.M. and Howley, P.M. Philadelphia: Lippincott-Raven; 2001.
49. Scherret, J.H., Poidinger, M., Mackenzie, J.S., Broom, A.K., Deu-bel, V., Lipkin, W.I., Briese, T., Gould, E.A., and Hall, R.A.: The relationships between West Nile and Kunjin viruses. Emerg Infect Dis. 7:697-705.2001.
50. Nash, D., Mostashari, F., Fine, A., Miller, J., O'leary, D., Murray, K., Huang, A., Rosenberg, A., Greenberg, A., Sherman, M., Wong, S. and Layton, M.: Te outbreak of West Nile virus infection in the New York City area in 1999. N. Engl. J. Med. 344, 1807-1814, 2001.
51. Carson, P.J, Konewko, P., Wold, K. S., Mariani, P., Goli, S., Berglof, P. and Crosby, R. D.: Long-term clinical and neuropsychologi-cal outcomes of West Nile virus infection. Clin. Infect. Dis. 43, 723-730, 2006.
52. Debiasi, R. L. and Tyler, K. L.: West Nile virus meningoencepha-litis. Nat. Clin. Pract. Neurol. 2: 264-275, 2006.
53. Hayes, E. B. and Gubler, D. J.: West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu. Rev. Med, 57: 181-194, 2006.
54. Hayes, E. B., Sejvar, J. J., Zaki, S. R., Lanciotti, R. S., Bode, A. V. and Campbell, G. L.: Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg. Infect. Dis. 11: 1174-1179, 2005.
55. Glass, W.G., McDermott, D.H., Lim, J.K., Lekhong, S., Yu, S.F., Frank, W.A., Pape, J., Cheshier, R.C. and Murphy, P.M.: CCR5 defciency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203:35-40, 2006.
56. Yakub, I., Lillibridge, K.M., Moran, A., Gonzalez, O.Y., Belmont, J., Gibbs, R.A. and Tweardy, D.J.: Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpa-tients hospitalized with West Nile virus infection. J. Infect. Dis. 192:1741-1748, 2005.
57. Ben-Nathan, D., Lustig, S., Tam, G., Robinzon, S., Segal, S. and Rager-Zisman, B.: Prophylactic and therapeutic efcacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J. Infect. Dis. 188:5-12, 2003.
58. Ben-Nathan, D., Gershoni-Yahalom, O., Samina, I., Khinich, Y., Nur, I., Laub, O., Gottreich, A., Simanov, A., Porgador, A., Rag-er-Zisman, B. and Orr, N.: Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect. Dis. 9:18. 2009.
59. Wang, T. and Fikrig, E.: Immunity to West Nile virus. Curr. Opin. Immunol. 16:519-523, 2004.
60. Mehlhop, E., and Diamond, M. S.: The molecular basis of antibody protection against West Nile virus. Curr. Top. Microbiol. Immunol. 317:125-153, 2008.
61. Beasley, D.W.: Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immuno-therapy. 3:269-285, 2011.
62. Hall, R.A. and Khromykh, A.A.: West Nile virus vaccines Expert Opinion on Biological Terapy. 4:1295-1305, 2007.
63. Lustig, S., Danenberg, H.D., Kafri, Y., Kobiler, D., and Ben-Nathan, D.: Viral neuroinvasion and encephalitis induced by li-popolysaccharide and its mediators. J. Exp. Med. 176:707-712, 1992.
64. Ben-Nathan, D., Huitinga, I., Lustig, S., Van Rooijen, N. and Kobiler, D.: West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch. Virol. 141:459-469, 1996.
65. Ben-Nathan, D., Lustig, S, Kobiler, D., Danenberg, H.D., Lupu, E. and Feuerstein, G.: Dehydroepiandrosterone protects mice inoculated with West Nile virus and exposed to cold stress. J. Med. Virol. 38:159-166, 1992.
66. Boumpas, D.T., Paliogianni, F., Anastassiou, E.D. and Balow, J.E.: Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin. Exp. Rheumatol. 9:413-423, 1991.
67. Scudeletti, M., Castagnetta, L., Imbimbo, B., Puppo, F., Pierri, I. and Indiveri, F.: New glucocorticoids. Mechanisms of immuno-logical activity at the cellular level and in the clinical setting. Ann. NY Acad. Sci.595:368-582, 1990.
68. Tuckermann, J.P., Kleiman, A., Moriggl, R., Spanbroek, R., Neumann, A., Illing, A., Clausen, B.E., Stride, B., Förster, I., Haben-icht, A.J., Reichardt, H.M., Tronche, F., Schmid, W. and Schütz, G.: Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J. Clin. Invest. 117:1381-1390, 2007.
69. Rickard, A. and Young, M.: Corticosteroid receptors, macrophag-es and cardiovascular disease. J. Mol. Endocrinol. 42:449-459, 2009.
70. Ben-Nathan, D., Kobiler, D., Feuerstein, G. and Lustig, S.: Anti-Stress efect of dihydroepiandronsterone (DHEA) on mice inoculated with attenuated arboviruses. Prog. NeuroEndocinImmu-nology 5:229-234, 1992.
71. Haydon, D.T., Kao, R.R. and Kitching, R.P.: The UK foot-and-mouth disease outbreak the aftermath. Nature Reviews Microbiology 2: 675-681, 2004.
72. Almeida, P.E., Weber, P.S.D., Burton, J.L. and Zanell, A.J.: Depressed DHEA and Increased sickness response behaviors in lamedairy cows with Infammatory foot lesions. Domestic Animal Endocrinology 34: 89-99, 2008.
73. Walz, P.H., Grooms, D.L., Passler, T., Ridpath, J.F., Tremblay, R., Step, D.L., Callan, R.J and Givens M.D.: Control of Bovine Viral Diarrhea Virus in Ruminants. J. Vet. Intern. Med. 24:476-486, 2010.
74. Schwartz-Cornil, I., Mertens, P.P.C., Contreras, V., Hemati1, B., Pascale, F., Bréard, E., Mellor, P.S.N., MacLachlan, N.J. and Zien-tara S.: Bluetongue virus: virology, pathogenesis and immunity. Vet. Res. 39:46, 2008.
75. Munier, S., Moisy, D., Marc, D. and Nafakh, N.: Interspecies transmission, adaptation to humans and pathogenicity of animal infuenza viruses Pathol. Biol. (Paris). 58: e59-68, 2010.
76. Harder, T.C. and Vahlenkamp, T.W.: Infuenza virus infections in dogs and cats. Vet. Immunol. Immunopathol. 134:54-60, 2010.
77. Padgett, D.A., Loria, R.M. and Sheridan, J. F.: Endocrine regulation of the immune response to infuenza virus infection with a metabolite of DHEA-androstenediol. J Neuroimmunol, 78, 203-211, 1997.
78. Padgett, D.A., MacCallum, R.C., Loria, R.M. and Sheridan, J.F.: Adrostenediol- induced restoration of responsiveness to Infu-enza vaccination in mice. Journal of Gerontology: 55A, B418- B424, 2000.